Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome

https://adler.staging1090.pendari.com/wp-content/uploads/2022/01/pharmaceutical-research-2021-09-24-03-47-46-utc-1.jpg 560 560 Adler Lab Adler Lab https://adler.staging1090.pendari.com/wp-content/uploads/2022/01/pharmaceutical-research-2021-09-24-03-47-46-utc-1.jpg November 26, 2018 February 2, 2022